Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status
- PMID: 21392246
- DOI: 10.1111/j.1471-0528.2011.02920.x
Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status
Abstract
Objective: To compare surgical outcomes and occult cancer rates at risk-reducing salpingo-oophorectomy in BRCA carriers and high-risk women who had not undergone genetic testing.
Design: Prospective cohort study.
Setting: Tertiary high-risk familial gynaecological cancer clinic.
Population: Women undergoing risk-reducing salpingo-oophorectomy between January 2005 and November 2009.
Methods: Women at high-risk of ovarian/tubal cancer were identified on the basis of the inclusion criteria for the UK Familial Ovarian Cancer Screening Study. Risk management options discussed with 1456 high-risk women included risk-reducing salpingo-oophorectomy. A strict histopathological protocol with serial slicing was used to assess tubes and ovaries.
Results: In total, 308 high-risk women (191 with unknown mutation status; 117 known BRCA1/BRCA2 carriers) chose risk-reducing surgery; 94.5% of procedures were performed laparoscopically. The surgical complication rate was 3.9% (95% CI 2.0-6.7). Four ovarian and ten tubal occult invasive/in situ cancers were found. The overall occult invasive cancer rate was 5.1% (95% CI 1.9-10.83) in BRCA1/BRCA2 carriers and 1.05% (95% CI 0.13-3.73) in untested women. When tubal in situ cancers were included, the overall rate was 4.55% (95% CI 2.5-7.5). Two untested women with tubal carcinoma in situ were subsequently found to be BRCA carriers. The median ages of BRCA carriers (58 years; IQR 13.4 years) and untested women (49.5 years; IQR 20.6 years) with occult invasive/in situ cancer were not significantly different (P = 0.454).
Conclusions: Both high-risk women of unknown mutation status and BRCA carriers have a significant (although higher in the latter group) rate of occult invasive/in situ tubal/ovarian cancer, with a similar age distribution at detection. The data has important implications for counselling high-risk women on the likelihood of occult malignancy and perioperative complications at risk-reducing salpingo-oophorectomy. Women with occult disease should be offered genetic testing.
© 2011 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2011 RCOG.
Similar articles
-
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21. Eur J Cancer. 2013. PMID: 22921157
-
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.Am J Obstet Gynecol. 2006 Jun;194(6):1702-9. doi: 10.1016/j.ajog.2006.03.006. Am J Obstet Gynecol. 2006. PMID: 16731090
-
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023992
-
Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16. J Minim Invasive Gynecol. 2013. PMID: 23332575 Review.
-
Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.Maturitas. 2011 Nov;70(3):261-5. doi: 10.1016/j.maturitas.2011.08.001. Epub 2011 Sep 4. Maturitas. 2011. PMID: 21893388 Review.
Cited by
-
Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281. CMAJ. 2019. PMID: 31405835 Free PMC article. Review. No abstract available.
-
The emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer.Front Immunol. 2025 Jan 6;15:1477781. doi: 10.3389/fimmu.2024.1477781. eCollection 2024. Front Immunol. 2025. PMID: 39835114 Free PMC article.
-
Cell Origins of High-Grade Serous Ovarian Cancer.Cancers (Basel). 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433. Cancers (Basel). 2018. PMID: 30424539 Free PMC article. Review.
-
Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation.Am J Case Rep. 2020 Feb 8;21:e921146. doi: 10.12659/AJCR.921146. Am J Case Rep. 2020. PMID: 32034117 Free PMC article.
-
Risk-reducing salpingectomy: Let us be opportunistic.Cancer. 2017 May 15;123(10):1714-1720. doi: 10.1002/cncr.30528. Epub 2017 Mar 23. Cancer. 2017. PMID: 28334425 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous